U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
127998
Substance Class Protein
Created
by admin
on Sun Dec 18 09:21:32 UTC 2022
Edited
by admin
on Sun Dec 18 09:21:32 UTC 2022
Protein Sub Type
Sequence Type COMPLETE
Record UNII
JQ83GG8LT2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM
Common Name English
PI3-KINASE SUBUNIT ALPHA
Common Name English
PTDINS-3-KINASE SUBUNIT ALPHA
Common Name English
PHOSPHOINOSITIDE-3-KINASE CATALYTIC ALPHA POLYPEPTIDE
Common Name English
PI3K-ALPHA
Common Name English
PIK3CA
Common Name English
Code System Code Type Description
DRUG BANK
DB14954
Created by admin on Sun Dec 18 09:21:36 UTC 2022 , Edited by admin on Sun Dec 18 09:21:36 UTC 2022
PRIMARY
FDA UNII
JQ83GG8LT2
Created by admin on Sun Dec 18 09:21:36 UTC 2022 , Edited by admin on Sun Dec 18 09:21:36 UTC 2022
PRIMARY
Related Record Type Details
Structure of PARSACLISIB
NON-INHIBITOR->OFF TARGET
IC50
Structure of PF-04691502
INHIBITOR -> TARGET
Structure of INAVOLISIB
INHIBITOR -> TARGET
selective for alpha isoform, and leads to degradation of mutant p110 alpha PI3K subunit.
Ki
Structure of ZSTK-474
INHIBITOR -> TARGET
Structure of IDELALISIB
WEAK INHIBITOR->TARGET
Structure of DACTOLISIB
INHIBITOR -> TARGET
Structure of PILARALISIB
INHIBITOR -> TARGET
Structure of COPANLISIB
INHIBITOR -> TARGET
INHIBITOR
IC50
Structure of SAMOTOLISIB
INHIBITOR -> TARGET
Structure of VDC-597
INHIBITOR -> TARGET
Structure of VOXTALISIB
INHIBITOR -> TARGET
Structure of APITOLISIB
PARENT->INNOVATOR
Structure of HS-173
INHIBITOR -> TARGET
IC50
Structure of OMIPALISIB
INHIBITOR -> TARGET
Structure of AZD-6482
INHIBITOR -> TARGET
Structure of ALPELISIB
INHIBITOR -> TARGET
IC50
Structure of BUPARLISIB
INHIBITOR -> TARGET
Structure of GDC-0326
INHIBITOR -> TARGET
Ki
Structure of GEDATOLISIB
INHIBITOR -> TARGET
Structure of IZORLISIB
INHIBITOR -> TARGET
Structure of PIK-75
INHIBITOR -> TARGET
IC50
Structure of PICTILISIB
INHIBITOR -> TARGET
Structure of CYH-33
INHIBITOR -> TARGET
IC50
Structure of Vulolisib
INHIBITOR -> TARGET
Structure of PUQUITINIB
INHIBITOR -> TARGET
COMPETITIVE INHIBITOR
Structure of BGT-226 FREE BASE
INHIBITOR -> TARGET
Structure of BAY-84-5975
INHIBITOR -> TARGET
INHIBITOR
IC50
Structure of TASELISIB
INHIBITOR -> TARGET
Ki
Structure of PAXALISIB
INHIBITOR -> TARGET
Structure of BAY-1082439
INHIBITOR -> TARGET
Structure of PF-06843195
INHIBITOR -> TARGET
Highly selective PI3K? inhibitor when tested at 1 ?M in a broad kinase panel (344 assays). >1000-fold selective over the members of class 2 (PI3K-C2?, PI3K-C2?), class 3 (hVPS34), and class 4 (PI3K?, PI4K?) groups of the PI3K family, PI3K-related (DNA-PK, mTOR) kinase family.
Ki
Structure of SONOLISIB
INHIBITOR -> TARGET
Structure of FIMEPINOSTAT
INHIBITOR -> TARGET
Structure of SERABELISIB
INHIBITOR -> TARGET
Selective, oral bioavailable PI3K? isoform inhibitor s more than 100-fold selective than other class I PI3K isoforms and mTOR as well as a high degree of selectivity against a large panel of protein kinases with potential antitumor activity.
IC50
Structure of RIGOSERTIB
INHIBITOR -> TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966